Evaluation of the efficacy of temsirolimus in patients with a recurrent bladder cancer after first-line chemotherapy. Clinical phase II multicenter.

Trial Profile

Evaluation of the efficacy of temsirolimus in patients with a recurrent bladder cancer after first-line chemotherapy. Clinical phase II multicenter.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Temsirolimus (Primary)
  • Indications Bladder cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms VESTOR
  • Most Recent Events

    • 19 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 03 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 09 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01827943).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top